BSEBoard Meeting7 Aug 2026 · 7 Aug 2026, 04:56 pm
Unaudited Standalone Financial Results along with the Limited Review Report For the Quarter ended June 30, 2026.
Venmax Drugs and Pharmaceuticals Ltd · 531015
✦ AI SummaryResults
Venmax Drugs and Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, along with a limited review report from its statutory auditors. The company has also approved the forfeiture of 7,80,001 partly paid-up convertible share warrants due to non-payment of the balance subscription amount within the prescribed period.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Venmax Drugs and Pharmaceuticals Ltd - 531015 - Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended June 30, 2026.